Meanwhile, an enhanced anti-tumor response of CD8+ T cells was observed in 2cKO tumor bearing mice treated with A2AR antagonist SCH58261, indicating the improvement of the immunosuppressive status. This evidence concerns the gene CD8A and neoplasm.